Related Experiment Video
Updated: Jul 2, 2026
12:27
Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration
Published on: June 7, 2014
Improved renal function after kidney transplantation is associated with heme oxygenase-1 polymorphism
K S Ozaki1, G M Marques, E Nogueira
1Nephrology Division, Universidade Federal de Säo Paulo, Brazil.
Clinical Transplantation
|May 8, 2008
Summary
Kidney transplant recipients from donors with the short (S) allele of the heme oxygenase-1 (HO-1) gene showed improved graft function. This benefit persisted even in patients with chronic allograft nephropathy.
Area of Science:
- Immunogenetics
- Transplantation immunology
- Nephrology
Background:
- Heme oxygenase-1 (HO-1) gene expression is regulated by microsatellite polymorphisms.
- The guanosine-thymidine (GT) repeat polymorphism in the HO-1 gene may influence organ survival post-transplant.
- Investigating HO-1 polymorphism's role in renal allograft function is crucial.
Purpose of the Study:
- To correlate heme oxygenase-1 (HO-1) gene polymorphism with renal allograft function.
- To determine if HO-1 GT repeat length impacts kidney graft survival and function post-transplantation.
Main Methods:
- Sequencing of the HO-1 gene in 181 kidney donors and recipients.
- Categorization of alleles into short (S) and long (L) repeat subclasses based on GT repeats.
- Statistical analysis correlating HO-1 polymorphism with allograft function at various time points.
Main Results:
- Donors with the short (S) allele (47.5%) were associated with improved allograft function six months, two, and three years post-transplantation.
- Recipients with the S allele (50.3%) showed better graft function, statistically significant at three years.
- In patients with chronic allograft nephropathy (CAN), both S allele donors and recipients exhibited improved allograft function at two and three years.
Conclusions:
- The short (S) allele of the heme oxygenase-1 (HO-1) gene is associated with enhanced renal allograft function.
- HO-1 polymorphism, specifically the S allele, may serve as a predictive marker for better kidney transplant outcomes, even in the presence of CAN.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...